Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anne Marit de Groot, Jeroen Stoop, Sarah Tete, Wim Van Damme, Isabel Leroux-Roels, Pieter-Jan Berghmans, Murray Kimmel, Pierre Van Damme, Jan de Hoon, Williams Smith, Kathryn E. Stephenson, Dan H. Barouch, Stephen C. De Rosa, Kristen W. Cohen, M. Juliana McElrath, Emmanuel Cormier, Gert Scheper, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Johan Van Hoof, Hanneke Schuitemaker
doi: https://doi.org/10.1101/2020.09.23.20199604
Jerald Sadoff
1Janssen Vaccines & Prevention, Leiden, The Netherlands
MDMathieu Le Gars
1Janssen Vaccines & Prevention, Leiden, The Netherlands
PhDGeorgi Shukarev
1Janssen Vaccines & Prevention, Leiden, The Netherlands
MDDirk Heerwegh
2Janssen Research & Development, Beerse, Belgium
PhDCarla Truyers
2Janssen Research & Development, Beerse, Belgium
PhDAnne Marit de Groot
1Janssen Vaccines & Prevention, Leiden, The Netherlands
PhDJeroen Stoop
1Janssen Vaccines & Prevention, Leiden, The Netherlands
PhDSarah Tete
1Janssen Vaccines & Prevention, Leiden, The Netherlands
PhDWim Van Damme
3Janssen Clinical Pharmacology Unit, Merksem, Belgium
MDIsabel Leroux-Roels
4CEVAC - University of Gent, Gent, Belgium
MDPieter-Jan Berghmans
5SGS Life Sciences, Antwerp, Belgium
MDMurray Kimmel
6Optimal Research LLC, Melbourne, Florida, USA
MDPierre Van Damme
8Centre for the Evaluation of Vaccination, University of Antwerp, Antwerp, Belgium
MDJan de Hoon
9Center for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium
MD, PhD, MsCWilliams Smith
10VRG and NOCCR, Knoxville, Tennessee, USA
MDKathryn E. Stephenson
11Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA
MDDan H. Barouch
11Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA
MDStephen C. De Rosa
12Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
MDKristen W. Cohen
12Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
PhDM. Juliana McElrath
12Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
MD, PhDEmmanuel Cormier
1Janssen Vaccines & Prevention, Leiden, The Netherlands
PhDGert Scheper
1Janssen Vaccines & Prevention, Leiden, The Netherlands
PhDJenny Hendriks
1Janssen Vaccines & Prevention, Leiden, The Netherlands
PhDFrank Struyf
2Janssen Research & Development, Beerse, Belgium
MDMacaya Douoguih
1Janssen Vaccines & Prevention, Leiden, The Netherlands
MD, MPHJohan Van Hoof
1Janssen Vaccines & Prevention, Leiden, The Netherlands
MDHanneke Schuitemaker
1Janssen Vaccines & Prevention, Leiden, The Netherlands
PhD![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
The data referred to in the manuscript will be available.
Posted September 25, 2020.
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anne Marit de Groot, Jeroen Stoop, Sarah Tete, Wim Van Damme, Isabel Leroux-Roels, Pieter-Jan Berghmans, Murray Kimmel, Pierre Van Damme, Jan de Hoon, Williams Smith, Kathryn E. Stephenson, Dan H. Barouch, Stephen C. De Rosa, Kristen W. Cohen, M. Juliana McElrath, Emmanuel Cormier, Gert Scheper, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Johan Van Hoof, Hanneke Schuitemaker
medRxiv 2020.09.23.20199604; doi: https://doi.org/10.1101/2020.09.23.20199604
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anne Marit de Groot, Jeroen Stoop, Sarah Tete, Wim Van Damme, Isabel Leroux-Roels, Pieter-Jan Berghmans, Murray Kimmel, Pierre Van Damme, Jan de Hoon, Williams Smith, Kathryn E. Stephenson, Dan H. Barouch, Stephen C. De Rosa, Kristen W. Cohen, M. Juliana McElrath, Emmanuel Cormier, Gert Scheper, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Johan Van Hoof, Hanneke Schuitemaker
medRxiv 2020.09.23.20199604; doi: https://doi.org/10.1101/2020.09.23.20199604
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (670)
- Anesthesia (181)
- Cardiovascular Medicine (2654)
- Dermatology (224)
- Emergency Medicine (400)
- Epidemiology (12245)
- Forensic Medicine (10)
- Gastroenterology (762)
- Genetic and Genomic Medicine (4113)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2665)
- Health Policy (1005)
- Hematology (364)
- HIV/AIDS (853)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (439)
- Neurology (3897)
- Nursing (210)
- Nutrition (578)
- Oncology (2037)
- Ophthalmology (586)
- Orthopedics (241)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1116)
- Primary Care Research (452)
- Public and Global Health (6538)
- Radiology and Imaging (1407)
- Respiratory Medicine (871)
- Rheumatology (411)
- Sports Medicine (343)
- Surgery (451)
- Toxicology (53)
- Transplantation (185)
- Urology (166)